LOXL3 and diffuse large B-cell lymphoma: Notably, overexpression of LOXL3 transcripts has been consistently observed in multiple malignancies, including adrenocortical carcinoma, invasive breast carcinoma, diffuse large B-cell lymphoma, esophageal carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, clear cell renal carcinoma, papillary renal cell carcinoma, acute myeloid leukemia, lower-grade gliomas, ovarian serous cystadenocarcinoma, cutaneous melanoma, gastric adenocarcinoma, and testicular germ cell tumors (Fig. 3B).